Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde
|
April 12, 2008
[Alternative flow chart for laboratory procedures for anemia]
J Droogendijk, M D Levin, J van der Meulen
Nederlands Tijdschrift Voor Geneeskunde
|
June 15, 2007
[Iron-deficiency anaemia: a sign that requires an adequate explanation]
J Droogendijk, P MacLean, P Berendes, et al.
Cancer
|
June 17, 2006
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial
Helga J Droogendijk, Hanneke J C Kluin-Nelemans, Jaap J van Doormaal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Noor Wortelboer, Seamus Kent, Inge R Konings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Journal of Geriatric Oncology
|
April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study
Joosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
Genome Medicine
|
August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Jonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
Jonathan E Knikman, Mirjam de With, Niels Heersche, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Nederlands Tijdschrift Voor Geneeskunde
|
April 12, 2008
[Alternative flow chart for laboratory procedures for anemia]
J Droogendijk, M D Levin, J van der Meulen
Nederlands Tijdschrift Voor Geneeskunde
|
June 15, 2007
[Iron-deficiency anaemia: a sign that requires an adequate explanation]
J Droogendijk, P MacLean, P Berendes, et al.
Cancer
|
June 17, 2006
Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial
Helga J Droogendijk, Hanneke J C Kluin-Nelemans, Jaap J van Doormaal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Noor Wortelboer, Seamus Kent, Inge R Konings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis
Jonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Journal of Geriatric Oncology
|
April 3, 2026
Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy: A prospective cohort study
Joosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, et al.
Genome Medicine
|
August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Jonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 4, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
Jonathan E Knikman, Mirjam de With, Niels Heersche, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
The Lancet. Oncology
|
October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Page
of 1